Document is current
Any future updates will be listed below
-
Authors
Shmara, Alyaa
Lee, Grace
Mgdsyan, Mania
Hall, Kathy
Sadri, Nadia
Martin-Rios, Angela
Valentine, Kelsey
Kain, Tatiana
Pahl, Madeleine
Polgreen, Lynda E.
Kimonis, Virginia https://orcid.org/0000-0003-1567-4449
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 26 May 2024
Accepted: 10 February 2025
First Online: 30 April 2025
Declarations
:
: Patients provided written informed consent for the IRB approved study at the University of California, Irvine (HS#2008–6631).
: Written informed consent was obtained from all the subjects included in the study. In the case of deceased patients, they provided their consents prior to their demise.
: VK is the Principal Investigator for the Rare Diseases Sanofi Registry at UC Irvine, CA. VK also receives funding for an outreach education program for FD. Co-authors GL, AMR and AS received fellowship funding from Sanofi. LEP has received research grants/contracts from BioMarin, Takeda, Sobi, and Pfizer, consulting fees from BioMarin and Denali, and honorarium and speaker fees from BioMarin.
